Innovative vaccines for a healthier world
Isconova AB is a leading international vaccine adjuvant company. With its vast knowledge of vaccine systems Isconova develops vaccines together with partners in the human and veterinary markets. Isconovas human vaccine adjuvant Matrix-M™ has been evaluated in two clinical phase I trials where is elicited strong humoral and cellular immune responses with a very good safety profile.
Launched vaccines with Isconova's adjuvant
Rabifel® - Rabies vaccine for cats, 2012, VetBioChem
Rabix® - Rabies vaccine for dogs, 2012, VetBioChem
Canvac CCi® - Bordetella bronchiseptica, 2007, Pfizer
Equilis® Prequenza - Equine influenza, 2006, Intervet, now MSD animal health
Pestigard® - Bovine BVDV, 2003, Pfizer
Equity® - Equine LHRH, 2002, Pfizer
Equip® - Equine influenza, 1993, Schering-Plough. From Oct. 2008, Pfizer
Human vaccines pipeline
From early stage development to clinical phase studies Matrix-M™ shows excellent results.
To the pipeline>>